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Purpose: Due to the availability of serum prostate specific antigen (PSA) testing, the 
detection rate of insignificant prostate cancer (IPC) is increasing. To ensure better 
treatment decisions, we developed a nomogram to predict the probability of IPC. 
Materials and Methods: The study population consisted of 1,471 patients who 
were treated at multiple institutions by radical prostatectomy without neoadjuvant 
therapy from 1995 to 2008. We obtained nonrandom samples of n = 1,031 for nomo-
gram development, leaving n = 440 for nomogram validation. IPC was defined as 
pathologic organ-confined disease and a tumor volume of 0.5 cc or less without 
Gleason grade 4 or 5. Multivariate logistic regression model (MLRM) coefficients 
were used to construct a nomogram to predict IPC from five variables, including se-
rum prostate specific antigen, clinical stage, biopsy Gleason score, positive cores ra-
tio and maximum % of tumor in any core. The performance characteristics were in-
ternally validated from 200 bootstrap resamples to reduce overfit bias. External 
validation was also performed in another cohort. Results: Overall, 67 (6.5%) pa-
tients had a so-called “insignificant” tumor in nomogram development cohort. PSA, 
clinical stage, biopsy Gleason score, positive core ratio and maximum % of biopsy 
tumor represented significant predictors of the presence of IPC. The resulting nomo-
gram had excellent discrimination accuracy, with a bootstrapped concordance index 
of 0.827. Conclusion: Our current nomogram provides sufficiently accurate infor-
mation in clinical practice that may be useful to patients and clinicians when various 
treatment options for screen-detected prostate cancer are considered. 
Key Words: Prostatic neoplasms, nomograms, insignificant
INTRODUCTION
With the widespread use of prostate-specific antigen (PSA) screening and extend-
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and prostatectomy specimen were recruited. Patients who 
received neoadjuvant hormonal treatment, prior transure-
thral resection or who had incomplete data were excluded. 
Finally, a total 1,471 patients were enrolled in this study. For 
the analyses, we drew nonrandom samples of n = 1,031 for 
nomogram development (e.g., according to center), leaving 
n = 440 for nomogram validation. Patient age, biopsy Glea-
son score, clinical stage, PSA, PSA density (PSAD), num-
ber of positive biopsy cores, and maximum % of tumor in 
any core were analyzed preoperatively in each case. Pros-
tate volume was measured by TRUS using the formula for 
elliptical volume (π/6 × height × width × length). PSAD 
was evaluated as the quotient of PSA and transrectal ultra-
sound (TRUS) estimated prostate volume (ng/mL/cc). 
Clinical stage was assigned, based on the 2002 TNM stag-
ing system.
　
Pathological evaluation
In all cases, the diagnosis was made by systematic biopsy 
(six cores or ≥ 10 cores). Positive core ratios were calculat-
ed by dividing the number of positive cores by the number 
of cores taken at TRUS biopsy. The maximum % of tumor 
in any core was defined as the greatest tumor percent 
among positive cores of biopsy. Insignificant tumors were 
defined as tumors with a total tumor volume in each speci-
men of less than 0.5 cc with organ confined disease and a 
histologic Gleason score of less than 7.7,8 Each radical pros-
tatectomy specimen was totally embedded and fixed in 10% 
neutral formalin. After fixation, the apex and base were am-
putated and serially sectioned at 4-mm intervals in the verti-
cal parasagittal plane. Tumor volume in the radical prosta-
tectomy specimen was calculated by multiplying the 
estimated percentage of cancer by the prostate volume. All 
histological grading of biopsies and prostatectomy speci-
mens was pathologically re-analyzed by nine uropatholo-
gists, who were members of the Korean genitourinary pa-
thology study group.
Statistical analysis
Continuous variables were compared using the Mann-
Whitney test, whereas categorical variables were compared 
via chi-square test. The effect of preoperative variables on 
the prediction of overall likelihood of IPC was analyzed via 
multivariate logistic regression models (MLRM). The dis-
crimination ability was quantified with receiver operating 
characteristic (ROC) analysis. Subsequently, MLRM coef-
ficients were used to generate a nomogram predicting the 
ed prostate biopsy strategy, the characteristics of newly di-
agnosed prostate cancer have changed. As the detection rate 
of small, low grade and localized prostate cancer has in-
creased, it is important to distinguish insignificant tumors 
from those that are potentially lethal if left untreated. Insig-
nificant prostate cancer refers to biologically indolent dis-
ease, typically found at autopsy, which is not destined to 
metastasize or otherwise threaten the life of the host.1 At 
present, active treatment, such as radical prostatectomy, ex-
ternal beam radiotherapy and brachytherapy, remains the 
gold standard for localized prostate cancer. However, no 
matter what treatment option is chosen, there is always a 
possibility of sexual and urinary dysfunction. Therefore, in 
cases of insignificant prostate cancer, active surveillance 
has been recommended as an attractive management option 
to avoid morbidity and potential mortality.2 However, the 
natural history of prostate cancer remains poorly under-
stood, and the selection criteria used to decide who should 
receive treatment and who might be able to be followed 
without immediate treatment are still controversial.
Recently, several studies have reported the development 
of statistical models for the prediction of insignificant pros-
tate cancer.3-6 A statistical model (nomogram) is an alterna-
tive method for assessing the probability of risk for a partic-
ular event using several variables. Several nomograms for 
insignificant prostate cancer have been constructed as tools 
for selecting patients for active surveillance. However, near-
ly all data are derived from Western populations, which may 
differ from Asian populations due to genetic variation and 
differences in prostate cancer screening systems. Moreover, 
there are no user-friendly tools applicable for Asian men 
that allow clinicians to predict the probability of insignifi-
cant prostate cancer. Therefore, we developed a model pre-
dicting the probability of insignificant prostate cancer (IPC)
in a multi-institutional cohort of Korean men by incorporat-
ing a detailed, quantitative assessment of biopsy results into 
a nomogram.
MATERIALS AND METHODS
Patient population
A consecutive series of 2,789 patients underwent radical 
prostatectomy for clinically localized prostate cancer at 14 
centers in Korea from 1995 to 2008. Men with complete 
data on clinical and pathological stage, preoperative serum 
PSA level, total cancer volume, Gleason score on biopsy 
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ables between significant and insignificant tumors, the ma-
jority variables had highly statistically significant differences 
as shown in Table 1 (p < 0.001). Table 2 shows that the mul-
tivariate regression analysis fitted in the development co-
hort. PSA, prostate volume (TRUS), clinical stage, biopsy 
Gleason score, positive core ratio and maximum % of biop-
sy tumor were observed to be independent predictors of the 
presence of IPC (all p values < 0.05). The performance 
(discrimination measurement) of the multivariate logistic 
regression model (MLRM) was demonstrated via the cal-
culated area under the ROC curve (AUC), which was 
0.847. Fig. 1A. shows the regression coefficient-based no-
mogram, which was devised from these predictor variables. 
Originally, we tried to fit PSAD into the nomogram; how-
ever, because the calibration of the generated nomogram 
did not show good properties, we decided to include PSA 
and prostate volume (TRUS) instead of PSAD in our no-
mogram. The nomogram is used by first locating the patient 
position on each predictor variable scale. Each scale posi-
probability of IPC at radical prostatectomy. Calibration was 
carried out for the constructed nomogram and internal vali-
dation was performed from 200 additional bootstrap sam-
ples to decrease the overfit bias. External validation was 
also performed in another cohort. Finally, various nomo-
gram probability cutoffs were tested to assess the ability to 
identify patients with or without IPC. All analyses were per-
formed using SAS version 9.1 statistical software (SAS In-
stitute, Cary, NC, USA) and R version 2.8.1 (The R Founda-
tion for Statistical Computing, Vienna, Austria). 
RESULTS
Histopathologic evaluation of prostatectomy specimens re-
vealed insignificant tumor in 67 (6.5%) of 1,031 patients. 
Of these 1031 patients, 98 (9%) underwent TRUS-guided 
preoperative sextant biopsy, while 933 (91%) underwent ex-
tended biopsy (≥ 10 cores) schemes. When comparing vari-
Table 1. Comparison of Variables between Significant and Insignificant Prostate Cancer
Variables
Subpopulation for nomogram
development (1,031) p value
Subpopulation for 
external validation (440)Significant Insignificant
No. of patients (%) 964 (93.5)   67 (6.5)
Mean age (yrs) 65.8 ± 7.4 62.8 ± 9.7    0.015 65.1 ± 8.1
Mean PSA (ng/mL) 12.7 ± 15.7 5.3 ± 6.9 < 0.001 9.8 ± 3.8
BMI (kg/m2) 23.5 ± 2.8  23.2 ± 3.1    0.401 23.6 ± 3.0
Prostate volume (cc) 37.1 ± 17.1 34.1 ± 11.3    0.047 36.8 ± 15.1
PSAD (ng/mL/cc) 0.42 ± 0.41 0.21 ± 0.11 < 0.001 0.38 ± 0.31
Biopsy gleason score (%)
    ≤ 6 352 (36.5) 63 (94.0) < 0.001 186 (42.3)
    7 454 (47.1) 4 (6.0) 186 (42.3)
    ≥ 8 158 (16.4) 0 (0.0) 68 (15.4)
Clinical stage
    T1c 482 (50.0) 52 (77.6) < 0.001 233 (53.0)
    T2a 202 (21.0)   9 (13.4) 110 (25.0)
    ≥ T2b 280 (29.0) 6 (9.0)   97 (22.0)
No. total biopsy cores obtained (%)
    6   96 (10.0) 2 (3.0) 37 (8.4)
    ≥ 10 868 (90.0) 65 (97.0) 403 (91.6)
Mean total biopsy core 10.8 ± 3.1 11.7 ± 2.5    0.109 11.3 ± 2.5
Mean No. positive core 3.9 ± 2.6 1.6 ± 1.5 < 0.001  3.4 ± 2.1
Mean positive core ratio 0.39 ± 0.25 0.13 ± 0.12 < 0.001  0.31 ± 0.17
Maximum % of tumor in any core 
  (range)
47.5 ± 31.3 16.8 ± 16.1 < 0.001  39.1 ± 26.0
PSA, prostate specific antigen; BMI, body mass index; PSAD, PSA density.
Data are presented as number (%) or mean ± standard deviation.
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(diagonal 45-degree dashed line). The solid line indicates 
bootstrap corrected nomogram performance. The internal 
validity of the multivariate model was evaluated by the 
bootstrap resampling method. The bootstrap-corrected 
AUC of the nomogram was 0.827. The external validation 
cohort data are represented by dotted line in Fig. 1C, where 
the curve represents the logistic calibration of the model. 
tion has corresponding prognostic points (top axis). The 
points for each variable are added and the probability of 
IPC is estimated from the bottom line. The graphical repre-
sentation of the accuracy of the nomogram is shown in Fig. 
1B, where the nomogram predicted probability is represent-
ed on the x-axis and the observed rate of IPC is plotted on 
the y-axis. Perfect prediction corresponded to a slope of 1 
Table 2. Multivariate Logistic Regression Analysis of Preoperative Predictors for Insignificant Prostate Cancer 
Variables Coefficient OR (95% CI) p value
Intercept   9.788
Age - 0.033 0.97 (0.93 - 1.03)    0.101
PSA - 0.054 0.95 (0.89 - 0.98)    0.043
TRUS   0.036 1.03 (1.01 - 1.06) < 0.001
Clinical stage - 0.309 0.77 (0.61 - 0.96)    0.023
Biopsy Gleason Score - 1.326 0.26 (0.14 - 0.51) < 0.001
Positive core ratio - 3.188 0.04 (0.01 - 0.43)    0.008
Max % of tumor at any biopsy site - 0.027 0.97 (0.94 - 0.99)    0.003
PSA, prostate specific antigen; TRUS, transrectal ultrasonograpy; OR, odds ratio; CI: confidence interval.
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Fig. 1. (A) Nomogram for predicting IPC in localized prostate cancer. Find the position of each variable on the corresponding axis, draw a 
line to the ‘points’ axis for the number of points, add the points from all the variables together, and draw a line from the ‘total points’ axis to 
determine the IPC probabilities at the bottom. (B) Calibration curves of preoperative nomogram in internal validation cohort. The x-axis is 
the predicted probability and the y-axis is the actual probability of IPC from the nomogram. The dashed line represents the ideal calibra-
tion curve for the nomogram (i.e., predicted probability completely corresponds with actual probability). The apparent accuracy without 
correction for over fit and bootstrap-corrected performance of our nomogram were represented by the dotted and solid line, respective-
ly. (C) Calibration plot of nomogram in external validation cohort (n = 440). Solid line indicates logistic calibration curve and dotted line 
represent data for validation cohort. IPC, insignificant prostate cancer.
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Generally, as not all prostate cancers pose a serious threat to 
life and consequently does not necessarily require therapy, 
it has been proposed that conservative management may be 
appropriate for those patients with IPC and a life expectan-
cy of less than 10 years, or for younger men with a favor-
able cancer, who are willing to accept the risk of metastases 
from an untreated tumor.3,12,13 However, men with IPC are 
often subjected to overtreatment with radical prostatectomy, 
because of difficulties in predicting the presence of IPC. 
Draisma, et al. has revealed that the lead times were 12.3 
and 6.0 years and overdetection rate were 27 and 56% in 
prostate-specific antigen screening tests at ages 55 and 75 
years.14 Therefore, it is necessary to diagnosis patients with 
clinically low-risk prostate cancers to avoid the problem of 
overtreatment.
Over the past few years, a considerable number of nomo-
grams have been constructed to predict IPC preoperatively. 
For instance, Kattan, et al.3 showed several nomograms that 
predict the probability of IPC (range of c-index, 64-79%). 
Those nomograms were externally validated in a screening 
cohort (range of c-index, 61-76%).15 Nakanishi, et al.4 at-
tempted to further improve the accuracy of the existing 
tools, especially in patients with a single positive core at bi-
opsy. In a cohort of 258 men, their model predicted with 
73% accuracy. Chun, et al.5 also suggested another statisti-
cal model with a predictive accuracy of 90.4% in a cohort 
of 1,132 men. These nomograms give clinicians many in-
formations about the decision-making process between de-
finitive therapy versus active surveillance.
In reality, however, most of the available reports on the 
The model curve and valiation cohort data show important 
departures from ideal prediction. The overall discrimination 
measurement of the validation cohort was 0.771.
Fig. 2A illustrates the ROC curve, based on the fitted mul-
tivariate logistic regression model. Fig. 2B illustrates the 
graph of positive predictive value (PPV)/negative predictive 
value (NPV) by various nomogram cutoffs. These figures are 
meant to assist clinicians in daily practice with identification 
of individuals with a particularly high chance for IPC, in 
whom active surveillance should be considered. 
 
DISCUSSION
Today, the natural history of screen-detected prostate cancer 
remains poorly understood. Autopsy studies have revealed 
that 50% of men in the age group of 40-49 years harbor 
prostate cancer.9 It is also said that about one-third of men 
older than 50 years of age will harbor prostate cancer at au-
topsy, whereas a man’s lifetime probability of developing 
invasive cancer is estimated to be 16.7% and the probabili-
ty of dying from it is approximately 2.5%.10,11 Epstein, et 
al.7 reported that 80% of these cancers are of low volume (< 
0.5 cc), and low grade, and can be classified as insignificant 
cancer. Insignificant cancer is usually defined as having a 
total tumor volume of less than 0.5 cc, being confined to 
the prostate with no focal or established extracapsular ex-
tension and having no Gleason grade 4 or 5. 
Traditionally, physician’s judgment has formed the basis 
for risk estimation, patient counseling and decision making. 
Fig. 2. (A) ROC curve based on the fitted multivariate logistic regression model. Sensitivity and 1-specificity are represented based on a cut-
off point (each dot) for IPC predicted probability. (B) The graph of PPV/NPV by nomogram cutoff. The x-axis indicates various cut off values 
and y-axis indicates the values of PPV/NPV. ROC, receiver operating characteristic; IPC, insignificant prostate cancer; PPV, positive predic-
tive value; NPV, negative predictive value.
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mor volume measurements were made primarily by visual 
estimation. Nevertheless, other studies have shown a strong 
correlation between the tumor volume estimates by visual 
inspection and grid morphometric analysis.24 Third, because 
our subjects were all Korean natives, the results of our study 
might have been different if our sample were more geo-
graphically diverse. This factor may undermine the accura-
cy of predictive nomogram in a specific population. 
Choosing a therapy involves curing as well as morbidity 
and quality of life issues. As a consequence, individual in-
formation on treatment and related morbidity are essential 
in treatment decision making for both doctor and patient. In 
that sense, this model can support patients and clinicians 
when various treatment options for screen-detected prostate 
cancer are considered. 
In conclusions, our nomograms for the prediction of in-
significant cancer provide more information than any cur-
rently available diagnostic test alone, while the currently 
used tumor prognostic factors, such as serum PSA, Gleason 
score, and clinical stage, provide general prognostic infor-
mation. The new nomogram, which is based on data from a 
large series of Korean patients, can predict insignificant 
cancer in Korean men more accurately than nomograms 
based on data from Western population. 
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